Altimmune
ALT----
Altimmune (ALT)
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate i...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Altimmune Analyst Rating
View MoreForecast & Rating
Jul 22, 2026Price forecast
$16.89470.57%
Forecast & RatingStrong buy
10analysts
- Strong buy70.00%
- Buy20.00%
- Hold10.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · Jul 9 at 05:02 AM
Biotech and CXO Clinical Momentum: 7 Core Companies Set for Late-2026 Breakouts
- benzinga_article · Jun 22 at 12:47 PM
Altimmune shares are trading higher after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $10 price target.
- Market Beat · Jun 10 at 08:05 AM
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near
- Market Beat · Jun 4 at 10:08 PM
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial
- StockTitan · May 28 at 02:00 AM
Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 | ALT Stock News
- Earnings Watch · May 13 at 03:23 PM
Altimmune | 10-Q: FY2026 Q1 Revenue Misses Estimate at USD 0
